Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?

Despite recommendations from medical societies, and support for its clinical and economic value, uptake of next-generation sequencing (NGS) has been slow in Europe, and access continues to be an issue. The gaps in funding and implementation are a significant barrier for patients with lung cancer benefitting from the use of NGS testing and the advanced precision treatments it facilitates.

In this 90-minute webinar, we built on the results of the recently published report by OHE and Takeda: ‘The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe’. Our expert panel shared insights from their diverse professional settings to capture the breadth of barriers, strategies and opportunities to increase access to NGS testing in lung cancer in different settings. The session ended with a panel discussion and an opportunity for the audience to ask questions to the speakers.

THE PANEL 

Professor Lotte Steuten |  Deputy Chief Executive, OHE. 

Lotte was the moderator for this session. She is a co-author of the report as well as expert in the field of economic evaluation of genetic diagnostics and precision oncology. She is a Visiting Honorary Professor at City University of London, and a member of the ISPOR Board of Directors. Lotte is also an associate editor for Value in Health and has published over 100 peer-reviewed papers.

Tanja Podkonjak | Director EUCAN Oncology Access and Reimbursement Policy, Takeda.

Tanja is a co-author of the report and member of the Takeda team. Tanja focuses on collaborating with stakeholders to shape the evolving access landscape for oncology medicines in Europe and Canada. Her main areas of focus are the EU Joint HTA Regulation, access to personalized medicines and combination medicines.  She has expertise in market access and HTA, leading multiple submissions to NICE and the Scottish Medicines Consortium.

Professor Mike Drummond | Professor of Health Economics, University of York.

Mike is a peer reviewer for the report. He is the author of more than 700 scientific papers, and has acted as a consultant to the World Health Organization. He has been President of the International Society for Pharmacoeconomics and Outcomes Research and is currently Co-Editor-in-Chief of Value in Health.

Professor Alastair Greystoke | Honorary Medical Oncologist, Newcastle’s Northern Centre for Cancer Care.

Alastair is a lecturer in Medical oncology at Newcastle University,  where he also leads the Pharmacodynamic Biomarker team. He is interested in the development of new anti-cancer drugs for patients with lung malignancies. He is also the Joint Chief Investigator for the CONCORDE platform.

Professor Frederique Penault- Llorca | Pathologist, University of Clermont- Ferrand.

Frederique is the CEO of the Comprehensive Regional Cancer Institute Centre Jean
PERRIN and Deputy Director of the research team INSERM 1240 IMoST. She is also Head of the Immuno-Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies, including the European Society for Medical Oncology. Frederique has over 400 publications and several books on female cancers and pathologic testing methods and issues.

WATCH IT ON DEMAND

This project was commissioned and funded by Takeda Pharmaceuticals International AG. The views expressed in this webinar are those of the speakers and do not necessarily represent the views of Takeda.

Job code: C-ANPROM/EUC/LC/0019                                      Date of Preparation: January 2024